Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. Materials and Methods A total of 77 patients were eligible for this study (38!in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)- AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). Results In patients with baseline PDGF-AA " median, median PFS was significantly worse in the TSU- 68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Conclusion Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.
Abstract
Purpose This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. Materials and Methods A total of 77 patients were eligible for this study (38!in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)- AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). Results In patients with baseline PDGF-AA " median, median PFS was significantly worse in the TSU- 68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Conclusion Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.
참고문헌 (14)
- Hicklin DJ, "Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis", J Clin Oncol, 23, pp.1011~1027 (2005)
- Reddy S, "Targeting angiogenesis in metastatic breast cancer", Oncologist, 17, pp.1014~1026 (2012)
- Laird AD, "SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors", Cancer Res, 60, pp.4152~4160 (2000)
- Suzuki Y, "A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane", Int J Clin Oncol, 18, pp.590~597 (2013)
- Toi M, "A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance", Breast Cancer, 21, pp.20~27 (2014)
- Kim SB, "Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial", Invest New Drugs, 32, pp.753~761 (2014)
- Murukesh N, "Biomarkers of angiogenesis and their role in the development of VEGF inhibitors", Br J Cancer, 102, pp.8~18 (2010)
- Shin SJ, "A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy", Invest New Drugs, 30, pp.1501~1510 (2012)
- Inaba Y, "A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation", Eur J Cancer, 49, pp.2832~2840 (2013)
- Pietras K, "PDGF receptors as cancer drug targets", Cancer Cell, 3, pp.439~443 (2003)
- Koizumi W, "Randomised phase II study of S-1", cisplatin plus TSU-68 vs S-1, Br J Cancer, pp.2013, 109[DOI]
- Ebos JM, "Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy", Proc Natl Acad Sci U S A, 104, pp.17069~17074 (2007)
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140, pp.883~899 (2010)
- Pierce BL, "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients", J Clin Oncol, 27, pp.3437~3444 (2009)